Vertex posts stronger-than-expected profit as new CF therapy drives sales surge
Vertex Pharmaceuticals reported first-quarter adjusted earnings that exceeded analyst estimates, fueled by a substantial rise in sales of its recently approved cystic fibrosis therapy Alyftrek. Total revenue rose 8% year-over-year, while sales of the company’s long-standing CF treatment Trikafta fell short of expectations. Management maintained its…